CIMS Fever Clinic

CIMS Fever Clinic

JCI

JCI

Isolation Unit

Isolation Unit

CIMS BREAST CANCER

CIMS BREAST CANCER

Global Healthcare Excellence Award 2018

Global Healthcare Excellence Award 2018

Diabetes Check

Diabetes Check

Dr Hemang Baxi

Name                                       Dr. Baxi Hemang Ashwinbhai

                                                MD, DM, FACC, FESC

 

Address                                   Office:

Care Institute of Medical Sciences

Nr. Shukan Mall

Off Science City Road, Sola

Ahmedabad-380060, Gujarat, India

Phone: +91-79-27712771(1-5 lines)

Fax:+91-79- 27712770

 

Residence:

A-401, Samay Apartment,

Nr. Azad Society,

Besides Vastrapur Telephone Exchange

Satellite, Ahmedabad 380 015.

Phone: (R) 2674 7703

(M) 98250 30111

 

Email Address             hemang.baxi@cims.me

 

Birth Date                    7th January 1969

 

Former Affiliations as Cardiologist:

  1. N. Mehta Heart Institute, Civil Hospital,

Ahmedabad.

  1. Rajasthan Hospital, Ahmedabad.
  2. Consultant and Interventional Cardiologist,

S.A.L., Ahmedabad.

 

Present Affiliations as Cardiologist:     1.   CIMS Hospital, Ahmedabad

  1.                        Sterling Hospital, Ahmedabad

                                                                       

Education:                               Schooling: St. Xavier High School, Gandhinagar, Gujarat.

Stood 8th in SSC Board, Gujarat.

 

Medical:    B. J. Medical College, Civil Hospital, Ahmedabad

 

Board (Degree)                         Bachelor of Medicine & Surgery (MBBS) 1992

Doctor of Medicine (MD) (Gen. Medicine) 1995

Doctor of Medicine (DM) (Cardiology) 1998 Gold Medalist

                                                Fellow of American College of Cardiology (FACC) – 2015

Fellow of  European College of Cardiology (FESC) – 2015

Fellowship Residency:             – Internship: July 1991-June 1992

Civil Hospital, Ahmedabad.

– Residency in Internal Medicine: July 1992- June 1995

Civil Hospital, Ahmedabad.

– Research Fellow at U N Mehta Cardiology Institute

Civil Hospital, Ahmedabad: July 1995 – Dec 1995

– Residency in Cardiology:  January 1996-April 1998

U N Mehta Heart Hospital, Ahmedabad.

– Research Fellow at U N Mehta Heart Hospital,

Ahmedabad:   April 1998- September 1998

 

Licensure:                                Gujarat Medical Council: G-20576

 

Professional Membership:       Life Member of Cardiac Society of India.

 

Professional Experience:         Interventional Cardiologist

  • Rajasthan Hospital : Oct 1998 to Sept 2001
  • Sterling Hospital : Oct 2001 to Feb 2004
  • A. L Hospital : March 2004 to 2010
  • CIMS Hospital : August 2010 onwards

 

Cardiac Interventions:              Over 10,000 Cardiac Catheterizations including complex

Coronary angiograms, valvular diseases, grafts, etc.

Over 4000 PTCA /Angioplasties including complex

Multivessel grafts, etc.

Over 800 cases in Primary/Rescue Angioplasties

Over 5000 stents used.

Over 500 Balloon Mitral Valvuloplasties

Over 50 Other valvular interventions

 

Peripheral Interventions:          Over 100 cases of Peripheral Interventions

Over 200 cases of Peripheral Diagnostic Angiography

Over 50 Percutaneous Intra vascular Stenting.

Over 50 Pacemaker implantation

 

Research Work and Publications:

 

  • Left main coronary artery disease in Gujarati population. Dr. Sameer Dani, Dr. Anish Chandarana, Dr. Jayesh Rawal, Dr. Bhupesh Shah, Dr. Urmil Shah, Dr. Sharad Jain, Dr. Hemang Baxi, Dr. Hasit Joshi.
  • Pulmonary Stenosis: Long term results of balloon dilatation. Dr. Sameer Dani, Dr. Jayesh Rawal, Dr. Bhupesh Shah, Dr. Sharad Jain, Dr. Urmil Shah, Dr. Hemang Baxi, Dr. Anish Chandarana, Dr. Hasit Joshi.
  • Combination of plain PTCA with stenting in coronary artery disease: immediate and intermediate-term outcome. Dr. S. I. Dani, Dr. B.R. Shah, Dr. U.G. Shah, Dr. H. Baxi, Dr. A. Chandarana, Dr. H. Joshi.
  • Intracoronary Saint Come stents: Short and mid-term follow up results. Dr. B.R. Shah, Dr. S.I. Dani, Dr. U.G. Shah, Dr. S. R. Jain, Dr. A. Chandarana, Dr. H. Baxi.
  • Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik AM, Goyal R.K. Effect of Folate Treatment on Homocysteinemia in Cardiac Patients: A Prospective Study: Indian J Pharmacol. (Abstract)
  • Parikh K.H., Chag M.C, Shah U.G, Baxi H.A., Chandarana A.H., Naik A.M, Goyal R.K., Shah K.J. Acute results and Intermediate term follow up of PCI with Cardioprotection by Balloon Occlusion Distal Protection Device. Indian Heart J. J-233, 2002; 54: 561-568.
  • Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Effect of Folate Treatment on Pharmacological Homocysteinemia in Cardiac Research Patients: A Prospective Study. Pharmacological Research (submitted) 2003.
  • Mehta K.N., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Effect of Folate Treatment on Homocysteinemia in Patients: A Prospective Study. Indian J Cardiol.2003; 5: 53
  • Shah K.J., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Reversal of Slow-Flow or No-Reflow in PTCA using boluses of IC Adenosine and Sodium Nitroprusside combination. Indian J Cardiol. 2003: 5: 38.
  • Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M.,Shah K.J., Goyal R.K. Reversal of Slow-Flow or No-Reflow in PTCA using Boluses of IC Adenosine and Sodium Nitroprusside. Suppl to JACC, March 19, 2003; 41 (6), Suppl A: 1101- 201
  • Shah K.J., Parikh K.H., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Prevalence of hyperhomocysteinemia in Western Indian Population with or without Coronary Artery Disease. Indian J Cardiol. (In Press).
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Beneficial effects of Distal Protection device in reducing the use of Intracoronary Vasodialators and Glycoprotein IIb/IIIa receptor antagonists during Percutaneous Coronary Interventions. (Accepted for Poster Presentation) Annual conference of Society of Cardiovascular Angiography and Interventions (SCAI) 2004
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Improvement in MACE by sequential administration of boluses of Intracoronary Adenosine and Sodium Nitroprusside during Percutaneous Coronary Interventions. (Accepted for Poster Presentation) Annual conference of Society of Cardiovascular Angiography and Interventions (SCAI) 2004
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Revascularization in Acute Myocardial Infarction using PercuSurge in Distal Protection. (Accepted for Poster Presentation) Annual conference of Society of Cardiovascular Angiography and Interventions (SCAI) 2004
  • Chag M.C., Shah H. D., Parikh K.H., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Increased Lipoprotein (a) as a strong risk factor for Coronary Artery Disease and the effect of Niacin amongst Indians. European Society of Cardiology (Submitted) 2004.
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Beneficial effects of Distal Protection device in reducing the use of Intracoronary Vasodialators and Glycoprotein IIb/IIIa receptor antagonists during Percutaneous Coronary Interventions. European Society of Cardiology (Submitted) 2004.
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Improvement in MACE by sequential administration of boluses of Intracoronary Adenosine and Sodium Nitroprusside during Percutaneous Coronary Interventions. European Society of Cardiology (Submitted) 2004.
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Revascularization in Acute Myocardial Infarction using PercuSurge in Distal Protection. European Society of Cardiology (Submitted) 2004.
  • Parikh K.H., Shah H. D., Chag M.C., Shah U.G., Baxi H.A., Chandarana A.H., Naik A.M., Goyal R.K. Effect of combination of statins and fenofibrate with acute coronary syndrome undergoing Percutaneous Coronary Interventions. European Society of  Cardiology (Submitted) 2004.

CLINICAL RESEARCH ACCOMPLISHED:

  • Effect of Folate treatment on Homocysteinemia in cardiac patients: A Prospective Study.
  • Pharmacoepidemiology and Risk factors of Hypertension in Gujarat.
  • Reversal of slow or no- reflow During Percutaneous Transluminal Coronary Angioplasty Using Boluses of Intracoronary Adenosine and Sodium Nitroprusside in combination.
  • Acute Results of Intermediate – term follow up of Percutaneous Transluminal Coronary Angioplasty with Cardioprotection by Balloon Occlusion Distal Protection Device.
  • Effect of Tirofiban HCl in Patients with Acute Coronary Syndrome and its comparison with other GPIIb/IIIa antagonists such as Abciximab and Eptifibatide
  • Revascularization Utilizing Balloon Protection in Acute Coronary ischemic Syndrome- An International Registry
  • An International Registry of CYPHER TM-Sirolimus eluting stent
  • High prevalence of Renal Artery Stenosis in Hypertensive patients with Triple vessel Coronary Artery Disease.
  • Effects of Combination of Statins and Fenofibrates with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention.
  • Effect of Pioglitazone and its combination with Statins in Coronary Artery Disease patients with Hsyperinsulinemia.
  • Comparison of Drug eluting stent with S7 stent.
  • Assessment of Risk factors for Coronary Artery Disease.
  • Effect of Niacin treatment on hyperlipoproteinemia in Coronary Artery Disease patients.
  • Beneficial effects of Distal Protection Device in reducing the use of Intracoronary Vasodialators and Glycoprotein IIb/IIIa receptor antagonists during Percutaneous Coronary Interventions.
  • Comparison of Total Procedural time involved in Primary PCI with or without the use of Distal Balloon Protection system in Thrombotic Coronary lesions. (RAPID trial- Revascularization in Acute myocardial infarction using Percusurge In Distal protection) 

INTERNATIONAL CLINICAL TRIALS: 

1 Co – Investigator for RUBY registry (For India) (2002) To evaluate Percusurge / Guardwire Distal Protection

Device (Presented by Dr. Aman, Switzerland)

Trial completed
2 Co – Investigator at Sterling Hospital for Extract-TIMI 25 Multicentre multi national Trial (2003) Enoxaparin and Thrombolysis Reperfusion for Acute

Myocardial Infarction Treatment Thrombolysis in

Myocardial Infarction –Study 25

Trial completed
3 Co – Investigator for  OASIS-5 Trial (2004) To evaluate the efficacy and safety of fondaparinux

versus Enoxaparin in the acute treatment of  unstable

angina or non ST-segment elevation myocardial

infarction acute coronary syndromes

Trial completed
4 Co – Investigator for  OASIS-6 Trial (2004) To evaluate the efficacy and safety of fondaparinux

Sodium versus control therapy and Glucose-Insulin-

Potassium infusion versus control in broad range in

patients with ST – segment elevation acute myocardial

infarction

Trial completed
5 Co – Investigator for TRUST Trial (2004) To evaluate the safety and efficacy of intravenous

Remodulin in patients( in India) With Pulmonary arterial

hypertension (PAH) in 12-week

Trial completed
6 Co-Investigator for Paediatric Hypertension Trial (2005) Dose ranging study to evaluate the  safety and efficacy

of Olmesartan medoxomil in children and adolescents

with hypertension

Trial completed
7 Co – Investigator for Hypercholesterol study (NK-104-301) at The Heart Care Clinic (2005) Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and

Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up

Titration ) in Patients with Primary Hypercholesterolemia

Or Combined Dyslipidemia

Trial completed
8 Co – Investigator for Neovasc Reducer™ Pilot Study, First in human: (2005) To evaluate the safety of the Neovasc Reducer™ in the treatment of Ischemic heart Disease (IHD), controlled narrowing of

the coronary sinus

Trial completed
9 Co – Investigator For PAPIRUS Trial: Pilot Study, First in Human: Apollo Hospital (2005) Monitoring Pulmonary Artery Pressure by Implantable

Device Responding to Ultrasonic

Signal (REMON Device)

Trial completed
10 Co – Investigator for Export study (2006) Flow improvement in patients with Acute Myocardial

Infarction undergoing either conventional stenting or

a strategy of primary aspiration followed by stenting using the Export Aspiration Catheter: a Prospective, Randomized, Controlled Study

 

Trial completed
11 Co – Investigator for E-five registry (for India) (2006) To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System.

 

Trial completed
12 Co- Investigator for RELY study (2006) Randomized Evaluation of Long term anticoagulant

therapy comparing efficacy and safety of two blinded

doses of dabigatran etexilate with open label warfarin for

the prevention of stroke and systemic embolism in

patients with non-valvular atrial fibrillation : prospective,

multi-centre, Parallel group, non-inferiority trial.

 

Trial completed

 

13 Co – Investigator for Hypercholesterolemia study (NK-104-307) at The Heart Care Clinic (2006) Open label, long-Term (1year) extension study of

Pitavastatin 4 mg QD in patients with Primary

Hypercholesterolemia or combined Dyslipidemia

Trial completed
14 Co – Investigator for  e-SELECT Registry (2007) The e-SELECT Registry : A Multicenter Post Marketing

Survelliance

 Trial completed
15 Co – Investigator for Early ACS trial (2007) Early Glycoprotein Iib/IIIa Inhibition in Non-ST- segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded  Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial completed
16 Co – Investigator  for PLATO trial (2007). A Randomised, Double-blind, Parallel Group, Phase 3,

Efficacy and safety study of AZD6140 Compares with

Clopidogrel for prevention of Vascular Events in

patients with Non-ST or ST Elevation Acute

Coronary Syndromes (ACS) [PLATO – A study of

Platelet inhibition and Patient Outcomes.]

Trial completed
17 Co – Investigator  for OASIS- 7 trial (2007) Randomized, multinational, double-blind study, comparing a high loading dose regimen of Clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy Trial completed

 

 

18 Co – Investigator  for New Guidewire (2007) First in Man: A Feasibility study to evaluate safety and efficacy of New Guide wire for Crossing Total Occlusions in Coronary Arteries Trial completed

 

19 Co-Investigator for Paediatric Hypertension Trial, The Heart Care Clinic, Ahmedabad (2007) A Randomized, double blind, Placebo-Controlled, Multicentre, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents Trial completed

 

20 Co-Investigator for Aristotle Trial at The Heart Care Clinic, Ahmedabad (2007) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: Active controlled randomized double blind parallel  arm study to evaluate efficacy and safety of Apixaban in subject with  non valvular Atrial fibrillation Follow-ups ongoing
21 Co-Investigator for Rocket Trial at The Heart Care Clinic, Ahmedabad (2007) Multicenter, Randomized, double-blind – dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once-daily oral Rivaroxabab (BAY 59-7939) with Adjusted-dose oral Warfarin for the prevention of Stroke and Non-central-nervous-system systemic embolism in Subjects with Non-valvular Atrial Fibrillation Follow-ups ongoing
22 Co – Investigator  for PROTECT Trial (2007) Patient Related Outcomes with Endeavor versus Cypher stenting Trial: Prospective, multicenter, randomized, two-arm, open-label trial Follow-ups ongoing
23 Co – Investigator  for TMC-CAN-05-02 (2007) A clinical trial comparing Cangrelor to Clopidogrel in subject who require Percutaneous Coronary Intervention Follow-ups ongoing
24 Co – Investigator  for TMC-CAN-05-03 (2008) A clinical Trial comparing treatment with Cangrelor (in combination with usual care) to usual care in subjects who require Percutaneous Coronary Intervention Follow-ups ongoing
25 Co – Investigator  for CL  (Ivabradine) at The Heart Care Clinic (2008) Evaluation of the anti-anginal efficacy Follow-ups ongoing
26 Co – Investigator  for  RE-DEEM at The Heart Care Clinic (2008)

 

Randomized Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: Multi-centre, prospective, placebo controlled, group dose escalation trial Trial completed
27 Co-Investigator for Magellan Trial (2008) A Multicenter, Randomized, parallel-group efficacy superiority study in hospitalize medically ill patients comparing rivaroxaban with Enoxaparin Follow-ups ongoing
28 Co-Investigator for Borealis Trial at The Heart Care Clinic Ahmedabad (2008) A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patient with atrial fibrillation Trial completed
29 Co – Investigator  for Freedom-PAH at The Heart Care Clinic FREEDOM UT –15C Studies (TDE-PH-302 and TDE-PH-304) conducted by United Therapeutics.

 

Ongoing
30 Co – Investigator  for ORBIT – 1 Pilot study to evaluate the safety & performance or the diamond back 360TM orbit Atherectomy system in treating de-NOVO calcified coronary lesions – orbit -1 Trial completed
31 Co-Investigator for AVERROES at The Heart Care Clinic CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation Trial completed
32 Co – Investigator  for Red-HF at The Heart Care Clinic A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction  and Anemia – 20050222 Amendment 1 Ongoing
33. Co – Investigator  for TAK-442-202 at The Heart Care Clinic A Phase II, double-blind, Randomized, Placebo-controlled study of the safety and Efficacy of TAK-442 in subjects with Acute Coronary Syndrome. Trial completed
34. Co – Investigator  for EISAI-202 at The Heart Care Clinic A Randomized, Double-Blind Placebo controlled study of the safety and tolerability of E5555 and its effect on clinical event and biomarkers in patient with Non ST segment Elevation Acute Coronary Syndrome. Trial completed
35 Co-Investigator for E-Resolute at the Heart Care Clinic Evaluation of the Endeavor Resolute Zolarolumes-Eluting Coronary Stent System in a ‘Real World’ Patient Population. Follow-up ongoing
36 Co – Investigator  of RIVAROXABAN at The Heart Care Clinic Randomized, Double Blind, Placebo Controlled, Event Driven, Multi Center Study To Evaluate The Efficacy And Safety Of Rivaroxaban In Subjects With Recent ACS. Follow-up ongoing
37 Co – Investigator of Pfizer PAH at The Heart Care Clinic B1321001 A Phase 3, Multi Center, Randomized, Double Blind, Placebo Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension. Ongoing
38 Co – Investigator  of Pfizer PAH at The Heart Care Clinic

B1321002

A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension. Ongoing
39 Co – Investigator of Pfizer PAH at The Heart Care Clinic B1321003 A Phase 3, Multi Center, Randomized, Double Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium and Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001. Ongoing
40 Co – Investigator  of LPL STABILITY at The Heart Care Clinic A Clinical Outcome Study Of Darapladib Versus Placebo In Subjects With Chronic Coronary Heart Disease To Compare The Incidence Of Major Adverse Cardiovascular Event. (MACE) Follow-up ongoing
41 Co – Investigator  of OASIS-8 at The Heart Care Clinic A Prospective Study Evaluating The Safety Of Two Regimens Of Adjustive Intravenous UFH PCI In High Risk Patients With UA/NSTEMI Initially Treated With Subcutaneous Fondaparinux And Referred For Early Coronary Angiography. Follow-up ongoing
42 Co-Investigator of STEM CELL A Randomized, Double Blind, Multi Centric, Placebo Controlled, Single Dose, Phase I/II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cell In Patients With ST Elevated Acute MI  (STEMI) Patient. Follow-up ongoing
44 Co – Investigator  for RUBY 1Trial at The Heart Care Clinic Ahmedabad (2010) A Randomized, Double Blind, Placebo Controlled, Multi

Center and Parallel Group Study of the Safety,

Tolerability, and Efficacy of YM150 in combination with

Standard  Treatment in Secondary Prevention of

Ischemic Vascular Events in Subjects with Acute

Coronary Syndromes.

Follow-up ongoing
45 Co – Investigator  for AmarinTrial at The Heart Care Clinic Ahmedabad (2010) A phase 3, multi center, placebo controlled, randomized,

double blind, 12 week study with an open label extension

to evaluate the efficacy And safety of AMR101 in patients

with fasting triglyceride levels > 500 mg/dl and

< 2000 mg/dl.

Follow-up ongoing
46 Co Investigator for SASHF RTrial at The Heart Care Clinic Ahmedabad (2008) South Asian Systolic Heart Failure Registry Ongoing
47 Co Investigator for TRAC HF Trial at The Heart Care Clinic Ahmedabad (2009) TRAC HF: Ambulatory Monitoring Using External

Physiological Sensors in Heart Failure Patients.

Ongoing
48 Co-Investigator for Alecardio trial at CIMS hospital Cardiovascular outcomes study  to evaluate the potential of aleglitazar  to reduce reduce  cardiovascular  risk in patients with

recent acute coronary syndrome (ACS) event and

type 2 diabetes mellitus (T2D)

Ongoing
49 Co-Investigator for Timi 52 trial at CIMS hospital A Clinical Outcomes Study of Darapaladib versus

Pleacebo in Subjects Following  Acute Coronary

Syndrome  to Compare the Incidence of Major Adverse

Cardiovascular Events (MACE)

Ongoing
50 Co-Investigator for Resolute Asia trial at CIMS hospital Evaluation of the Endevor Resolute Zotarolimus-Eluting

Coronary Stent System in a Patient Population with

Long Lesion(s) aand/or Dual Vessels in Asia;

Prospective, Multi-center, Non-randomized Study.

Ongoing
51 Co-Investigator for Appraise-2 trial A Phase 3, Randomized, Double-blind, Evaluation of

the safety and Efficacy of Apixaban in subjects with a

Recent Acute Coronary Syndrome

 

Follow-up ongoing

 NATIONAL CLINICAL TRIALS 

1 Co – Investigator  for BIVAFLO Registy (2006) To evaluate the efficacy and safety of BIVAFLO® as an

adjunctive therapy during PCI in moderate-high risk

ACS patients with provisional GP IIb/IIIa inhibitors use.

Trial completed
2 Co – Investigator  for CORREL + C  Trial (2006) The COREL C  Registry : A multicentre Post marketing

Surveillance for clinical and angiographic evaluation of

Corel C stent.

Trial completed
3 Principal Investigator for POLYCAP Trial at VS hospital Ahmedabad(2007) A randomized double blind controlled trial of the efficacy

And safety of POLYCAP Vs its components in subjects

With at least one additional cardiovascular risk factor

Trial completed
4 Co – Investigator for ACUNOVA Trial (2006-2007) A phase III, open label, multicentre, parallel group,

Randomized study to evaluate the safety and efficacy of

Abciximab in Indian patients scheduled for Percutaneous

Coronary Intervention.

Trial completed
5 Co – Investigator for ZYHI Trial at The Heart Care Clinic Ahmedabad (2007) (1) A randomized, double blind parallel group, prospective

dose ranging study of  ZYH 1 with an open fenofibrate arm

to evaluate the efficacy on dyslipidemia in patients without

diabetes  Protocol No. 2001 Ver: 01

(2) A randomized, double blind parallel group, prospective

dose ranging study of ZYH1 with an open pioglitazone arm

to evaluate the efficacy. on dyslipidemia in patients with

diabetes Protocol No. 2003  Ver: 02

(3) A randomized, double blind parallel group, prospective

dose ranging study of  ZYH 1 with an open pioglitazone

arm to evaluate the efficacy on dyslipidemia in patients

with impaired glucose test Protocol No.2004  Ver: 02                           

 

 

Trial completed
Web Design MymensinghPremium WordPress ThemesWeb Development

CIMS GlobL Healthcare Excellence Awards 2018

October 30, 2018
CIMS Family is honoured to be the recipient of “Among Best Hospital (Cardiology & Oncology) in Gujarat” on October 27, 2018 at the “Prime Time Global Healthcare Excellence Awards 2018”, New Delhi. A very special thanks to our CIMS Staff for their commitment and the patients who have always trusted us. CIMS GlobL Healthcare Excellence Awards 2018

CIMS Hospital has been awarded the Certificate of Excellence as the Best Multispecialty Hospital in Gujarat

August 31, 2018
We proudly announce that CIMS Hospital has been awarded the Certificate of Excellence as the Best Multispecialty Hospital in Gujarat at the International Healthcare Awards, 2018 held in Delhi. The Award is a testimony to the hard work and dedication of the entire CIMS Family which has inspired trust in us leading to rising patient volumes.

Certificate course in EMG & NCV Technology

May 15, 2018

Renal Transplant (CIMS/RIC/2018/09) on 15/05/2018

May 15, 2018
Renal Transplant is done on 15/05/2018, which was approved by Hospital based Ethical committee and Government Authorization committee. Relationship between Donor and Recipient : Wife - Husband

We are proud to announce that CIMS Hospital has been recognized as the Times Health Icon 2018 in 2 categories

March 19, 2018
We are proud to announce that CIMS Hospital has been recognized as the Times Health Icon 2018 in 2 categories Multispecialty Hospital- Oncology and Multispecialty Hospital-Critical Care.

CIMS Heart Transplant Team completes another successful Heart Transplant on 06-02-2018, 5th row in a short term.

February 8, 2018

Felicitation Ceremony of Heart Transplant Donors and Recipients held in the presence of Honorable Chief Minister of Gujarat, Shri Vijay Rupani, CIMS cardiac and heart tranplantation doctors by CIMS Hospital.

January 12, 2018
Felicitation Ceremony of Heart Transplant Donors and Recipients held in the presence of Honorable Chief Minister of Gujarat, Shri Vijay Rupani, CIMS cardiac and heart tranplantation doctors by CIMS Hospital.